메뉴 건너뛰기




Volumn 120, Issue 11, 2013, Pages 2300-2309

Ranibizumab versus bevacizumab for neovascular age-related macular degeneration: Results from the GEFAL noninferiority randomized trial

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; RANIBIZUMAB;

EID: 84887176870     PISSN: 01616420     EISSN: 15494713     Source Type: Journal    
DOI: 10.1016/j.ophtha.2013.06.020     Document Type: Article
Times cited : (231)

References (23)
  • 1
    • 1942542429 scopus 로고    scopus 로고
    • Age-related macular degeneration is the leading cause of blindness
    • N.M. Bressler Age-related macular degeneration is the leading cause of blindness JAMA 291 2004 1900 1901
    • (2004) JAMA , vol.291 , pp. 1900-1901
    • Bressler, N.M.1
  • 2
    • 37449010146 scopus 로고    scopus 로고
    • The natural history and prognosis of neovascular age-related macular degeneration: A systematic review of the literature and meta-analysis
    • T.Y. Wong, U. Chakravarthy, and R. Klein The natural history and prognosis of neovascular age-related macular degeneration: a systematic review of the literature and meta-analysis Ophthalmology 115 2008 116 126
    • (2008) Ophthalmology , vol.115 , pp. 116-126
    • Wong, T.Y.1    Chakravarthy, U.2    Klein, R.3
  • 3
    • 84856002562 scopus 로고    scopus 로고
    • Incidence of legal blindness from age-related macular degeneration in Denmark: Year 2000 to 2010
    • S.B. Bloch, M. Larsen, and I.C. Munch Incidence of legal blindness from age-related macular degeneration in Denmark: year 2000 to 2010 Am J Ophthalmol 153 2012 209 213
    • (2012) Am J Ophthalmol , vol.153 , pp. 209-213
    • Bloch, S.B.1    Larsen, M.2    Munch, I.C.3
  • 4
    • 33749445317 scopus 로고    scopus 로고
    • Ranibizumab for neovascular age-related macular degeneration
    • MARINA Study Group
    • P.J. Rosenfeld, D.M. Brown, J.S. Heier MARINA Study Group Ranibizumab for neovascular age-related macular degeneration N Engl J Med 355 2006 1419 1431
    • (2006) N Engl J Med , vol.355 , pp. 1419-1431
    • Rosenfeld, P.J.1    Brown, D.M.2    Heier, J.S.3
  • 5
    • 33749451356 scopus 로고    scopus 로고
    • Ranibizumab versus verteporfin for neovascular age-related macular degeneration
    • ANCHOR Study Group
    • D.M. Brown, P.K. Kaiser, M. Michels ANCHOR Study Group Ranibizumab versus verteporfin for neovascular age-related macular degeneration N Engl J Med 355 2006 1432 1444
    • (2006) N Engl J Med , vol.355 , pp. 1432-1444
    • Brown, D.M.1    Kaiser, P.K.2    Michels, M.3
  • 6
    • 2542561964 scopus 로고    scopus 로고
    • Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
    • H. Hurwitz, L. Fehrenbacher, and W. Novotny Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N Engl J Med 350 2004 2335 2342
    • (2004) N Engl J Med , vol.350 , pp. 2335-2342
    • Hurwitz, H.1    Fehrenbacher, L.2    Novotny, W.3
  • 7
    • 79955085045 scopus 로고    scopus 로고
    • Pharmacotherapy for neovascular age-related macular degeneration: An analysis of the 100% 2008 Medicare fee-for-service part B claims file
    • R.J. Brechner, P.J. Rosenfeld, J.D. Babish, and S. Caplan Pharmacotherapy for neovascular age-related macular degeneration: an analysis of the 100% 2008 Medicare fee-for-service part B claims file Am J Ophthalmol 151 2011 887 895
    • (2011) Am J Ophthalmol , vol.151 , pp. 887-895
    • Brechner, R.J.1    Rosenfeld, P.J.2    Babish, J.D.3    Caplan, S.4
  • 8
    • 58949093226 scopus 로고    scopus 로고
    • Primary intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration: Results of the Pan-American Collaborative Retina Study Group at 12 months follow-up
    • J.F. Arevalo, J. Fromow-Guerra, and J.G. Sanchez Primary intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration: results of the Pan-American Collaborative Retina Study Group at 12 months follow-up Retina 28 2008 1387 1394
    • (2008) Retina , vol.28 , pp. 1387-1394
    • Arevalo, J.F.1    Fromow-Guerra, J.2    Sanchez, J.G.3
  • 9
    • 84858139464 scopus 로고    scopus 로고
    • Cost-utility analysis of bevacizumab versus ranibizumab in neovascular age-related macular degeneration using a Markov model
    • J.J. Patel, M.A. Mendes, and M. Bounthavong Cost-utility analysis of bevacizumab versus ranibizumab in neovascular age-related macular degeneration using a Markov model J Eval Clin Pract 18 2012 247 255
    • (2012) J Eval Clin Pract , vol.18 , pp. 247-255
    • Patel, J.J.1    Mendes, M.A.2    Bounthavong, M.3
  • 10
    • 61349102385 scopus 로고    scopus 로고
    • Economic implications of current age-related macular degeneration treatments
    • W.E. Smiddy Economic implications of current age-related macular degeneration treatments Ophthalmology 116 2009 481 487
    • (2009) Ophthalmology , vol.116 , pp. 481-487
    • Smiddy, W.E.1
  • 11
    • 84863327423 scopus 로고    scopus 로고
    • Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: One-year findings from the IVAN randomized trial
    • IVAN Study Investigators, U. Chakravarthy, S.P. Harding, and C.A. Rogers Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial Ophthalmology 119 2012 1399 1411
    • (2012) Ophthalmology , vol.119 , pp. 1399-1411
    • Chakravarthy, U.1    Harding, S.P.2    Rogers, C.A.3
  • 12
    • 84875260404 scopus 로고    scopus 로고
    • Diffusion of technologies for the care of older adults with exudative age-related macular degeneration
    • J.D. Stein, B.W. Hanrahan, G.M. Comer, and F.A. Sloan Diffusion of technologies for the care of older adults with exudative age-related macular degeneration Am J Ophthalmol 155 2013 688 696
    • (2013) Am J Ophthalmol , vol.155 , pp. 688-696
    • Stein, J.D.1    Hanrahan, B.W.2    Comer, G.M.3    Sloan, F.A.4
  • 13
    • 33644792767 scopus 로고    scopus 로고
    • Reporting of noninferiority and equivalence randomized trials: An extension of the CONSORT statement
    • CONSORT Group
    • G. Piaggio, D.R. Elbourne, D.G. Altman CONSORT Group Reporting of noninferiority and equivalence randomized trials: an extension of the CONSORT statement JAMA 295 2006 1152 1160
    • (2006) JAMA , vol.295 , pp. 1152-1160
    • Piaggio, G.1    Elbourne, D.R.2    Altman, D.G.3
  • 14
    • 79956218863 scopus 로고    scopus 로고
    • Ranibizumab and bevacizumab for neovascular age-related macular degeneration
    • CATT Research Group, D.F. Martin, M.G. Maguire, and G.S. Ying Ranibizumab and bevacizumab for neovascular age-related macular degeneration N Engl J Med 364 2011 1897 1908
    • (2011) N Engl J Med , vol.364 , pp. 1897-1908
    • Research Group, C.1    Martin, D.F.2    Maguire, M.G.3    Ying, G.S.4
  • 15
    • 84863320414 scopus 로고    scopus 로고
    • Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: Two-year results
    • Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group
    • Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group, D.F. Martin, M.G. Maguire, and S.L. Fine Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results Ophthalmology 119 2012 1388 1398
    • (2012) Ophthalmology , vol.119 , pp. 1388-1398
    • Martin, D.F.1    Maguire, M.G.2    Fine, S.L.3
  • 16
    • 84874654113 scopus 로고    scopus 로고
    • A randomised double-masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age-related macular degeneration
    • MANTA Research Group
    • I. Krebs, L. Schmetterer, A. Boltz MANTA Research Group A randomised double-masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age-related macular degeneration Br J Ophthalmol 97 2013 266 271
    • (2013) Br J Ophthalmol , vol.97 , pp. 266-271
    • Krebs, I.1    Schmetterer, L.2    Boltz, A.3
  • 17
    • 84872026174 scopus 로고    scopus 로고
    • Baseline predictors for one-year visual outcomes with ranibizumab or bevacizumab for neovascular age-related macular degeneration
    • Comparison of Age-related Macular Degeneration Treatments Trials Research Group
    • G.S. Ying, J. Huang, M.G. Maguire Comparison of Age-related Macular Degeneration Treatments Trials Research Group Baseline predictors for one-year visual outcomes with ranibizumab or bevacizumab for neovascular age-related macular degeneration Ophthalmology 120 2013 122 129
    • (2013) Ophthalmology , vol.120 , pp. 122-129
    • Ying, G.S.1    Huang, J.2    Maguire, M.G.3
  • 18
    • 84874948393 scopus 로고    scopus 로고
    • Changes in visual acuity in patients with wet age-related macular degeneration treated with intravitreal ranibizumab in daily clinical practice: The LUMIERE study
    • LUMIERE Study Group
    • S.Y. Cohen, G. Mimoun, H. Oubraham LUMIERE Study Group Changes in visual acuity in patients with wet age-related macular degeneration treated with intravitreal ranibizumab in daily clinical practice: the LUMIERE study Retina 33 2013 474 481
    • (2013) Retina , vol.33 , pp. 474-481
    • Cohen, S.Y.1    Mimoun, G.2    Oubraham, H.3
  • 19
    • 53449093792 scopus 로고    scopus 로고
    • Intersession repeatability of visual acuity scores in age-related macular degeneration
    • P.J. Patel, F.K. Chen, G.S. Rubin, and A. Tufail Intersession repeatability of visual acuity scores in age-related macular degeneration Invest Ophthalmol Vis Sci 49 2008 4347 4352
    • (2008) Invest Ophthalmol Vis Sci , vol.49 , pp. 4347-4352
    • Patel, P.J.1    Chen, F.K.2    Rubin, G.S.3    Tufail, A.4
  • 20
    • 84856344197 scopus 로고    scopus 로고
    • Computerized repeating and averaging improve the test-retest variability of ETDRS visual acuity measurements: Implications for sensitivity and specificity
    • N. Shah, D.A. Laidlaw, and S.P. Shah Computerized repeating and averaging improve the test-retest variability of ETDRS visual acuity measurements: implications for sensitivity and specificity Invest Ophthalmol Vis Sci 52 2011 9397 9402
    • (2011) Invest Ophthalmol Vis Sci , vol.52 , pp. 9397-9402
    • Shah, N.1    Laidlaw, D.A.2    Shah, S.P.3
  • 21
    • 69249213449 scopus 로고    scopus 로고
    • Evaluation of injection frequency and visual acuity outcomes for ranibizumab monotherapy in exudative age-related macular degeneration
    • H. Dadgostar, A.A. Ventura, and J.Y. Chung Evaluation of injection frequency and visual acuity outcomes for ranibizumab monotherapy in exudative age-related macular degeneration Ophthalmology 116 2009 1740 1747
    • (2009) Ophthalmology , vol.116 , pp. 1740-1747
    • Dadgostar, H.1    Ventura, A.A.2    Chung, J.Y.3
  • 22
    • 79955066891 scopus 로고    scopus 로고
    • Meta-analysis of endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents: Causative organisms and possible prevention strategies
    • C.A. McCannel Meta-analysis of endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents: causative organisms and possible prevention strategies Retina 31 2011 654 661
    • (2011) Retina , vol.31 , pp. 654-661
    • McCannel, C.A.1
  • 23
    • 84862907626 scopus 로고    scopus 로고
    • An outbreak of Streptococcus endophthalmitis after intravitreal injection of bevacizumab
    • R.A. Goldberg, H.W. Flynn Jr., and R.F. Isom An outbreak of Streptococcus endophthalmitis after intravitreal injection of bevacizumab Am J Ophthalmol 153 2012 204 208
    • (2012) Am J Ophthalmol , vol.153 , pp. 204-208
    • Goldberg, R.A.1    Flynn Jr., H.W.2    Isom, R.F.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.